A single arm, open-label trial assessing the effect of Capecitabine (Xeloda�) on progression-free survival rate at four months in breast cancer patients with CNS progression after whole brain radiotherapy

To evaluate the efficacy of capecitabine in terms of Progression Free Survival (PFS) rate at 4 months, reviewed by centralized independent expert, in treatment of brain metastases secondary to breast cancer in patients with CNS progression after whole brain radiotherapy (WBRT).